Introduction
============

Mesenchymal stem cells (MSCs) are multipotent cells capable of self-renewal, and they can give rise to a number of unique differentiated mesenchymal cell types.^[@bib1],\ [@bib2]^ MSCs are attractive candidates for clinical applications for the repair or regeneration of damaged tissues because their isolation is convenient and they lack significant immunogenicity, permitting allogenic transplantation without immunosuppressive drugs. Moreover, there is no ethical controversy on MSCs, and they have the potential to differentiate into tissue-specific cell types.^[@bib3],\ [@bib4]^ However, the use of MSCs in tissue regeneration has been limited mainly because they have a low proliferation rate and limited lifespan, and they progressively lose their stem cell properties during *in vitro* expansion.

To induce pluripotent stem cells or to improve the stemness of MSCs, forced expression of pluripotent cell-specific factors (Oct4, Sox2, Nanog and cMyc) or combinations of these genes for reprogramming somatic or adult stem cells^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ has been shown to induce highly efficient successful reprogramming into pluripotent cells.^[@bib6]^ Among the four pluripotent factors, Oct4 and Sox2 are transcription factors essential to pluripotent and self-renewing phenotypes.^[@bib10],\ [@bib11]^ It is well known that Oct4 is a key transcription factor essential for self-renewal and survival of MSCs,^[@bib7],\ [@bib8],\ [@bib12]^ and it has a unique role in the development and determination of pluripotency. This gene constitutes the core regulatory network that suppresses differentiation-associated genes, thereby maintaining pluripotency of the cells.^[@bib13]^ Sox2 has a critical role in the maintenance of embryonic and neural stem cells and holds great promise in research involving induced pluripotency. Furthermore, Go *et al.*^[@bib5]^ observed that Sox2 is not only essential for pluripotency and self-renewal of embryonic stem cells, but is also expressed in somatic stem cells with superior expansion and differentiation potential.

Both Oct4 and Sox2 are naturally expressed in both embryonic stem cells and adult stem cells. However, they are usually expressed at low levels in early-passage MSCs and gradually decrease as the passage number increases.^[@bib6],\ [@bib7]^ Several researchers have studied the effect of Oct4 or Sox2 overexpression in MSCs,^[@bib5],\ [@bib6],\ [@bib9],\ [@bib14]^ but the results are still debatable. Although their roles are not clearly identified in MSCs, it seems apparent that Oct4 and Sox2 have reciprocal actions.^[@bib15],\ [@bib16],\ [@bib17]^ However, the effect of co-expression of Oct4 and Sox2 in MSCs has not been investigated. In this study, we co-expressed Oct4 and Sox2 with the aim of conferring higher capabilities for proliferation and differentiation.

Materials and methods
=====================

Cell cultures
-------------

Human adipose tissues were obtained by simple liposuction of abdominal subcutaneous fat from a donor after obtaining informed consent according to the guidelines of the Institutional Review Board (IRB) of the K-STEMCELL, Seoul, Korea. Cells were maintained in RKCM (MSC proliferation media, K-STEMCELL) at subconfluent levels to prevent spontaneous differentiation.

Generation of Oct4/Sox2-overexpressing human ATMSCs
---------------------------------------------------

Oct4-IRES-Sox2 was inserted into the PB-CA vector (Addgene, Cambridge, MA, USA). Human adipose tissue MSCs (ATMSCs) were then transfected with the Oct4-IRES-Sox2 vector using D-fection transfection reagent (Lugen Sci, Seoul, Korea) according to the manufacturer\'s instructions. Oct4/Sox2-containing plasmid and D-fection complex were added to the cells in the appropriate volume of ATMSC culture medium. Cells were fed with fresh culture medium at 24 h after transfection. Transfected cells were frozen at either P4 or P5 to make cryopreserved cell stocks. For cellular analyses, we used the transfected cells directly (P4 or P5), or thawed the cryopreserved cells. Red fluorescent protein (RFP) inserted into the PB-CA vector was used as a control, and it was generated using the same methods.

Flow cytometric analysis of cell surface marker expression in ATMSCs
--------------------------------------------------------------------

To analyze the cell surface marker expression in RFP- and Oct4/Sox2-ATMSCs, flow cytometry was performed. By passage 5, a homogenous population of rapidly dividing cells with fibroblastoid morphology was obtained. ATMSCs were fixed with 70% ethanol at 4 °C and stained for 30 min on ice with primary antibodies that recognize various surface molecules. Phycoerythrin-conjugated (PE) mouse anti-human CD29 (BD Biosciences, San Jose, CA, USA), FITC (fluorescein isothiocyanate-conjugated) mouse anti-human CD31 (BD Biosciences), PE mouse anti-human CD34 (BD Biosciences), FITC mouse anti-human CD44 (BD Biosciences), FITC mouse anti-human CD45 (BD Biosciences), PE mouse anti-human CD73 (BD Biosciences Pharmingen, San Diego, CA, USA), PE mouse anti-human CD90 (BD Biosciences), and PE anti-human CD105/endoglin (R&D system, Minneapolis, MN, USA) were used for cell surface antigen detection. The immunophenotype of MSCs was analyzed using a FACS Calibur flow cytometer (BD Biosciences, Bedford, MA, USA) with CELLQuest software (BD Biosciences).

RT--PCR analysis
----------------

Total RNA was isolated from RFP- or Oct4/Sox2-transfected ATMSCs using Trizol (Invitrogen, Carlsbad, CA, USA) following the manufacturer\'s protocol. Briefly, samples were transferred to a tube containing 1 ml of RNA extraction solution. The homogenate was then extracted with chloroform, precipitated using isopropanol, washed with ethanol and then resuspended in 30 μl distilled water. RNA concentration and purity were determined using a Nanophotometer (Implen, Munich, Germany) at 260 and 280 nm. Samples exhibited an absorbance ratio (260/280) of ⩾1.8. The first-strand cDNA was obtained by reverse transcription using 3 μg total RNA, M-MuLV RT and an oligo(dT)-18 primer, according to the manufacturer\'s instructions (Invitrogen). Primer sequences are shown in [Table 1](#tbl1){ref-type="table"}. PCR products were electrophoresed on 1.5% agarose gels to verify DNA fragment sizes.

Cell proliferation analysis
---------------------------

To determine the effects of Oct4/Sox2 overexpression on MSC proliferation rates, cell proliferation and viability were evaluated by WST-1 cell proliferation and trypan blue exclusion assays. For the WST-1 cell proliferation assay, cells were seeded in 96-well plates at 5 × 10^3^ cells/well. Each cell was assayed in triplicate, including RFP-ATMSCs wells. Cells were then incubated for 4 (day 0), 24 (day 1), 48 (day 2) and 72 h (day 3), and then 10 μl WST-1 reagent was added to each well. The reaction proceeded for 2 h at 37 °C with 5% CO~2~. The absorbance of the samples at 450 nm was measured using a microplate reader.

For trypan blue exclusion, ATMSCs were seeded into six-well culture plates at 1 × 10^5^ cells/well in duplicate and then incubated at 37 °C with 5% CO~2~. After day 1, 2, 3, 5, 7 and 9, cells were collected and stained with 0.4% trypan blue solution. Enumeration of viable cells was carried out under a phase contrast microscope with a hemocytometer.

Cell cycle analysis
-------------------

Three days after transfection, ATMSCs were washed twice with PBS and harvested by trypsinization. The cells were then washed again with PBS and fixed with 70% ethanol at −20 °C for 1 day. The fixed cells were washed with ice-cold PBS and stained with 50 μg ml^−1^ propidium iodide (Sigma, St. Louis, MO, USA) in the presence of 100 μg ml^−1^ RNase A (Sigma) for 30 min. The cell cycle was analyzed using a FACS Calibur flow cytometer (BD Biosciences).

Western blot analysis
---------------------

After RFP- and Oct4/Sox2-ATMSCs were collected by centrifugation, the pellet was resuspended in lysis buffer (25 m[M]{.smallcaps} Tris, pH 7.5, 150 m[M]{.smallcaps} NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing proteinase inhibitors and incubated on ice for 30 min. Following centrifugation at 16 000 × g for 15 min at 4 °C, the supernatant containing the total cell extract was collected and kept at −80 °C. Protein from the cell extracts were electrophoresed and transferred onto a Hybond-PVDF membrane (Amersham Biosciences, Piscataway, NJ, USA). The membrane was incubated for 1 h at room temperature in blocking buffer (TBS-T containing 5% skim milk) to block nonspecific protein binding and then incubated overnight at 4 °C with a primary antibody against Oct4 (1:1000), Sox2 (1:500), cyclin D1 (1:1000) or β-actin (1:1000) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) diluted in blocking buffer. The membrane was washed with TBS-T and incubated with secondary antibody diluted (1:3000) in blocking buffer for 1 h at room temperature. Antibody binding was visualized with a West-Q Chemiluminescent Substrate Plus Kit (GenDEPOT, Barker, TX, USA).

Osteogenic and adipogenic differentiation
-----------------------------------------

Human RFP or Oct4/Sox2-ATMSCs that were ∼80% confluent were induced to differentiate into adipocytes or osteocytes for 21 days in adipogenic or osteogenic media, respectively.

To induce adipogenic differentiation, both RFP- and Oct4/Sox2-ATMSCs were plated at a density of 5 × 103 cells cm^−2^ in adipogenic induction medium (Gibco, Grand Island, NY, USA). The medium was changed every 3 days. After 7, 14 and 21 days, cells were fixed with 4% paraformaldehyde and oil red O staining was conducted to identify lipid droplets.

To induce osteogenic differentiation, both RFP- and Oct4/Sox2-ATMSCs were plated at a density of 5 × 103 cells cm^−2^ (Gibco). The medium was changed every 3 days. After 7, 14 and 21 days, cells were fixed with 4% paraformaldehyde and alizarin red S staining was performed to assess the mineralized matrix content.

Statistical analysis
--------------------

All experiments were performed at least twice. Values are expressed as mean+standard deviation. The probability associated with a Student\'s *t*-test was performed for comparison of the parameters between two groups. *P*-values \<0.05 were considered statistically significant.

Results
=======

Expression analysis of Oct4 and Sox2 in ATMSCs transfected with *Oct4/Sox2* genes
---------------------------------------------------------------------------------

To assess Oct4 and Sox2 expression in ATMSCs transfected with *Oct4/Sox2* genes (Oct4/Sox2-ATMSCs), we performed RT--PCR and western blot analysis ([Figure 1](#fig1){ref-type="fig"}). The levels of *Oct4* and *Sox2* mRNA were significantly higher in ATMSCs than in RFP-ATMSCs, whereas the expression levels of *Oct4* and *Sox2* in RFP-ATMSCs were almost undetectable. Concurrently, the western blot analysis results revealed that the expression of Oct4 and Sox2 protein was significantly upregulated in Oct4/Sox2-ATMSCs. These results showed that Oct4/Sox2-ATMSCs were successfully generated by liposomal transfection.

Immunophenotyping of both RFP- and Oct4/Sox2-ATMSCs
---------------------------------------------------

The surface markers CD29, CD44, CD73, CD90, CD105, CD31, CD34 and CD45 were used to evaluate whether the immunophenotypic characteristics of ATMSCs changed with gene transfection at passage 5. Flow cytometry analysis showed high expression of CD29, CD44, CD73, CD90 and CD105, and the absence of CD31, CD34 and CD45 surface markers on both RFP- and Oct4/Sox2-transfected ATMSCs ([Figure 2](#fig2){ref-type="fig"}). There were no differences in expression of surface markers in ATMSCs with both gene modifications. The result of flow cytometric analyses indicates that the expression of ATMSC surface markers is not changed by Oct4/Sox2 gene transfection.

Enhanced proliferative potential of Oct4/Sox2-ATMSCs
----------------------------------------------------

To assess the proliferative ability of Oct4/Sox2-ATMSCs, we examined cell growth by WST-1 assay, which measures cell viability relative to the metabolic activity ([Figure 3a](#fig3){ref-type="fig"}). The Oct4/Sox2 overexpression in ATMSCs resulted in a time-dependent increase in proliferation. This result was further confirmed by trypan blue exclusion assay ([Figure 3b](#fig3){ref-type="fig"}), which serves as an index of cell viability. It was apparent that the number of viable Oct4/Sox2-ATMSCs was increased significantly compared with that of RFP-ATMSCs. The data demonstrate that Oct4/Sox2-expressing ATMSCs have much higher expansion potential and cell viability than control cells (RFP-ATMSCs).

Acceleration of the G1 to S phase transition in Oct4/Sox2-ATMSCs
----------------------------------------------------------------

We evaluated the effects of Oct4/Sox2 overexpression on the cell cycle ([Figure 4a](#fig4){ref-type="fig"}) based on our previous finding that Oct4/Sox2 overexpression promotes cell proliferation. Cell cycle analysis by flow cytometry showed that in Oct4/Sox2-ATMSCs, 67.99±0.69% of cells were in the G0/G1 phase, 14.38±0.84% were in the S phase and 17.65±1.36% were in the G2/M phase. However, the percentage of S and G2/M phase cells in RFP-ATMSCs was much lower (7.59±0.62%, 16.73±0.93%). All Oct4/Sox2-ATMSCs had a reduction in the fraction of cells in G1 with a concomitant increase in the fraction of cells in S compared with RFP-ATMSCs.

To verify cell cycle progression, we assessed the changes in the protein levels of a major regulator, cyclin D1, which promotes G1-to-S-phase transition and cell proliferation. As shown in [Figure 4b](#fig4){ref-type="fig"}, Oct4/Sox2 upregulation in ATMSCs resulted in increased cyclin D1 expression. These data show that Oct4/Sox2 overexpression promotes ATMSC proliferation, at least in part, by promoting the transition of cells from G1 to S phase.

Improved adipogenic and osteogenic differentiation of Oct4/Sox2-ATMSCs
----------------------------------------------------------------------

To study the effect of Oct4/Sox2 overexpression on the pluripotency of ATMSCs, we examined the differentiation potential of Oct4/Sox2-ATMSCs into adipocytes and osteoblasts. We assessed the differentiation potency by comparing the staining intensity and the expression of fat and bone genes at the transcriptional level. The staining intensity of oil red O for lipid droplets in Oct4/Sox2-ATMSCs was stronger than that in RFP-ATMSCs, suggesting that Oct4/Sox2 expression promotes adipogenesis of ATMSCs ([Figure 5a](#fig5){ref-type="fig"}). To validate these results, we analyzed lineage-specific gene expression. Peroxisome proliferator-activated receptor gamma (PPARγ) and lipoprotein lipase, genetic markers of adipose tissue, were upregulated after Oct4/Sox2 overexpression ([Figure 5b](#fig5){ref-type="fig"}). Similarly, alizarin red S staining intensity was much stronger in Oct4/Sox2-ATMSCs than in RFP-ATMSCs ([Figure 6a](#fig6){ref-type="fig"}). Consistent with these phenotypic results, markers of osteogenic differentiation (collagen I and osteocalcin) were upregulated by *Oct4/Sox2* gene engineering ([Figure 6b](#fig6){ref-type="fig"}). The results of the gene expression patterns and phenotypic analyses indicate that Oct4/Sox2 overexpression significantly promotes the ability of ATMSCs to differentiate into adipocytes and osteoblasts.

Discussion
==========

In the present study, we successfully engineered ATMSCs to overexpress Oct4 and Sox2 by using a PB-CA vector, which has the advantage of integration into the host cell genome. The PB-CA vector backbone requires the PBase vector to 'piggyBac transpose\' and has a high copy number. After 24 h transfection with Oct4/Sox2 in ATMSCs, Oct4/Sox2-ATMSCs appear to show no differences in cell morphology compared with non-transfected ATMSCs although a low level of cell death was observed in the liposomally transfected cells. RT--PCR demonstrated high efficiency of exogenous *Oct4* and *Sox2* production, and high Oct4 and Sox2 protein levels were detected by western blot. In addition, immunophenotyping by flow cytometric analysis showed that the genetic modification of ATMSCs with Oct4/Sox2 did not alter MSC surface markers.

The results of WST-1 and trypan blue exclusion assays showed that Oct4/Sox2-overexpressing cells had significantly higher viability and proliferation rates than control cells. These results were further evaluated in cell cycle progression by cell cycle analysis and western blot analysis of cyclin D1. The cell cycle is a series of events that occurs in a cell leading to its division and replication, and is a critical process for determining cell proliferation and senescence.^[@bib6]^ The G0/G1 phase is the non-proliferative or resting phase; the S phase involves DNA replication; in G2, the cell is ready for division; and in the M phase, mitosis occurs. In this study, Oct4/Sox2 overexpression in ATMSCs resulted in an extended S phase. Cell cycle progression is tightly regulated by cyclins, and cyclin D1 is the first cyclin produced in the cell cycle. Upregulation of cyclin D1 can cause premature entrance into the S phase, indicating a rate-limiting role for cyclin D1 in the G/S transition.^[@bib18],\ [@bib19]^ The expression of cyclin D1 influences cell cycle progression and consequently, stem cell proliferation. Taken together, these results indicate that Oct4/Sox2 overexpression causes high enough levels of cyclin D1 for the cell to initiate DNA replication and be in the extended S phase, resulting in cell growth and proliferation. Thus, these observations appear to indicate a stronger effect of Oct4/Sox2 expression on cell proliferation compared with control cells, at least in part, by accelerating the transition of cells from G1 to S phase.

We showed that Oct4/Sox2 overexpression increased the number of positive cells stained with oil red O or alizarin red S and the expression of adipogenic or osteogenic markers, indicating an enhanced capacity of Oct4/Sox2-ATMSCs for differentiation towards adipogenesis or osteogenesis. This result means that the overexpression of Oct4 and Sox2 increased differentiation ability in the prepared differentiation media containing all reagents required for inducing MSCs to be committed to the adipogenesis and osteogenesis pathway. The effect of Oct4 and Sox2 on the differentiation mechanism of stem cells was studied by other some researchers. Ben-Shushan *et al.*^[@bib20]^ reported that the down regulation of Zfp42 mRNA (preventing differentiation) caused by induction of elevated Oct-4 is consistent with the finding that overexpression of Oct-4 represses activation of the Zfp42 promoter mediated via Rox-1. The increasing the levels of Sox2, and thus limiting the expression of several Sox2:Oct-4 target genes (*Oct4, Nanog, FGF-4, UTF-1, Lefty-1* and *BMP4*) that are critical for stem cell pluripotency, may trigger the differentiation of cells.

As *Oct4* and *Sox2* are important at the transcriptional level to maintain pluripotency in embryonic stem cells,^[@bib10],\ [@bib11],\ [@bib21]^ their expression level is important within the framework of stem cell differentiation. Thus, it is well known that Oct4 levels govern the balance between differentiation and de-differentiation and that maintaining Oct4 expression within a certain range appears to be critical for stem cell renewal, with any increase or decrease triggering differentiation to endoderm/mesoderm or trophectoderm, respectively.^[@bib22]^ In contrast with Oct4, overexpression of Sox2 promotes embryonic stem cells to differentiate into cells that express a wide range of markers associated with neuroectoderm and mesoderm, as well as markers for trophectoderm cells.^[@bib23]^ It has been reported that increase of twofold or less in the levels of Sox2 triggers cell differentiation. On the basis of these studies, a proper level of overexpression of these genes is crucial for inducing stimulation of the cell stemness. Our results showing that co-overexpression of *Oct4* and *Sox2* genes effectively enhanced mesodermal differentiation potency indicates increased stemness of ATMSCs.

In MSC research, studies on overexpression of pluripotent genes in MSCs are not well identified and are still controversial. Lim *et al.*^[@bib7]^ established stable Oct4-overexpressing MSCs and showed that this promoted cell proliferation and improved adipogenesis and chondrogenesis. Conversely, Nanog overexpression has been shown to slow down adipogenesis of MSCs. In other studies, increases in both Nanog and Oct4 increased proliferation and trilineage differentiation potential but decreased spontaneous differentiation, suggesting that Oct4 and Nanog are not only essential for the maintenance of pluripotency in embryonic stem cells but also for maintaining MSC properties.^[@bib24]^ However, Jaganathan and Bonnet^[@bib14]^ reported that exogenous Oct4 induced early senescence, as evidenced by increased expression of p16INK4a and p14, which are key regulators of cellular senescence in MSCs. Sox2 is also important for maintaining proliferation and osteogenic differentiation potentials of MSCs,^[@bib5]^ and replicative senescence and multipotentiality of MSCs during *in vitro* expansion may be regulated predominantly through Sox2.^[@bib6]^ Although their roles in MSCs are still controversial, *Oct4* and *Sox2* have been described previously to drive pluripotent-specific expression of a number of genes through cooperative interaction.^[@bib25]^ Chew *et al.*^[@bib16]^ showed that Oct4 and Sox2, which bind independently to their respective binding motifs, act synergistically to activate these enhancers. Furthermore, the Oct--Sox enhancers regulate the expression of pluripotent stem cell-specific genes, including *Nanog, Oct4* and *Sox2* itself, suggesting that this enhancer is at the top of the pluripotent cell genetic regulatory network.^[@bib15]^ For these reasons, the study of Oct4 and Sox2 has provided major insights into the transcriptional circuitry responsible for sustaining the self-renewal and pluripotency of embryonic stem cells. Therefore, we selected these two transcriptional genes for genetic modification of ATMSCs and showed that Oct4 and Sox2 overexpression significantly affect the cell viability and stemness of ATMSCs in an *in vitro* culture system.

In the advancement of stem cell therapy, the acquisition of clinically relevant numbers of stem cells in a timely manner and the maintenance of stem cell properties are challenging issues.^[@bib26],\ [@bib27]^ In this context, MSCs transduced with Oct4/Sox2 have useful clinical applications because they have short culture duration, and costs and labor are reduced. Furthermore, Oct4 and Sox2 improved adipogenic and osteogenic differentiation, which may have resulted from enhancement of ATMSC stemness. Multilineage capacity and proliferation *in vitro* were interpreted at the time as indicative of *in vivo* multipotency and self-renewal properties--the hallmarks of 'stemness.\'^[@bib28]^ In conclusion, our data suggest that Oct4/Sox2 gene engineering could be a useful method for gaining high-quality ATMSCs with shortened culture time and the ability to meet efficacy endpoints in clinical studies of MSC-based tissue engineering.
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![Expression analysis of Oct4 and Sox2 in Oct4/Sox2-ATMSCs. (**a**) In RT--PCR analysis, the mRNA expression levels of Oct4 and Sox2 in Oct4/Sox2-ATMSCs were significantly higher than those of RFP-ATMSCs at 24 h post-transfection. Band densities in RT--PCR were evaluated semi-quantitatively by densitometry. Results are the ratio of Oct4 and Sox2 expression normalized to GAPDH mRNA levels. (**b**) Western blots show high levels of Oct4 and Sox2 expression in Oct4/Sox2-ATMSCs. Band densities in western blot analysis were evaluated semi-quantitatively by densitometry. Results are the ratio of Oct4 and Sox2 expression normalized to beta-actin protein levels. Data are representative of three independent experiments, with similar results. Data are expressed as the means+s.d. *\*\*P\<*0.01 compared with the control (RFP-ATMSCs) value as determined by Student\'s *t*-test.](emm201428f1){#fig1}

![Immunophenotyping of RFP- and Oct4/Sox2-transfected ATMSCs. Non-transfected MSCs at passage 3, RFP-transfected ATMSCs at passage 5 and Oct4/Sox2-transfected ATMSCs at passage 5 were immunophenotyped for CD29, CD31, CD34, CD44, CD45, CD73, CD90 and CD105 by flow cytometry. The expression of surface markers of ATMSCs transduced with Oct4/Sox2 or RFP were not different from those of non-transfected ATMSCs. Data are representative of three independent experiments, with similar results.](emm201428f2){#fig2}

![Proliferation assay using Oct4/Sox2-ATMSCs. (**a**) WST-1 assay showed that Oct4/Sox2-ATMSCs have higher cell metabolic activity than RFP-ATMSCs at 1, 2 and 3 days. (**b**) In the trypan blue exclusion assay, viable cell numbers were increased significantly in Oct4/Sox2-ATMSCs cultured for 9 days compared with RFP-ATMSCs. Data are expressed as the mean±s.d. \*\**P*\<0.01 compared with the corresponding control value as determined by Student\'s *t*-test.](emm201428f3){#fig3}

![Cell cycle analysis by flow cytometry, and western blot analysis of cyclin D1 in Oct4/Sox2-ATMSCs. (**a**) Representative flow cytometry results of RFP- and Oct4/Sox2-ATMSCs (**b**) The percentage of cells at each cell cycle stage as determined by flow cytometry analysis. Compared with the control (RFP-ATMSCs), cell cycle analysis showed a decrease in the proportion of Oct4/Sox2-ATMSCs in the G0/G1 phase, whereas an increase was observed in the proportion of those in the S phase. (**c**) The expression of cyclin D1, which is a major regulator, was increased in Oct4/Sox2-ATMSCs compared with RFP-ATMSCs. Data are expressed as the mean+s.d. \*\**P*\<0.01 compared with the corresponding control value as determined by Student\'s *t*-test.](emm201428f4){#fig4}

![Adipogenic differentiation assay using Oct4/Sox2-ATMSCs and RT--PCR analysis for adipogenic markers. (**a**) Oil red O staining for lipid droplets in Oct4/Sox2-transfected ATMSCs was strong at 7, 14 and 21 days during adipogenic differentiation compared with RFP-ATMSCs. (**b**) RT--PCR results show a significant increase in PPARγ and lipoprotein lipase mRNA expression at 7, 14 and 21 days during adipogenic differentiation. Band densities of PPARγ in RT--PCR were evaluated semi-quantitatively by densitometry. Results are the ratio of PPARγ expression normalized to GAPDH mRNA levels. Data are representative of three independent experiments with similar results. (1) RFP-ATMSCs, (2) Oct4/Sox2-ATMSCs.](emm201428f5){#fig5}

![Osteogenic differentiation assay using Oct4/Sox2-ATMSCs and RT--PCR analysis for osteogenic markers. (**a**) Alizarin red S staining for mineralization in Oct4/Sox2-ATMSCs was strong at 7, 14 and 21 days during osteogenic differentiation compared with RFP-ATMSCs. (**b**) RT--PCR results show upregulation of collagen I and osteocalcin mRNA levels in Oct4/Sox2-ATMSCs at 7, 14 and 21 days during osteogenic differentiation compared with RFP-ATMSCs. Band densities of collagen I and osteocalcin in RT--PCR were evaluated semi-quantitatively by densitometry. Results are the ratio of collagen I and osteocalcin expression normalized to GAPDH mRNA levels. Data are representative of three independent experiments with similar results. (1) RFP-ATMSCs, (2) Oct4/Sox2-ATMSCs.](emm201428f6){#fig6}

###### Primer sequences for RT--PCR amplification of target genes

  *Gene*                    *Primer*              *Gene Bank accession number*  *Product size (bp)*
  ------------- -------------------------------- ------------------------------ ---------------------
  Oct4           F: 5′-TGCAGAAAGAACTCGAGCAA-3′            NM_002701.4           1082
                 R: 5′-ACACTCGGACCACATCCTTC-3′                                   
  Sox2           F: 5′-AGAACCCCAAGATGCACAAC-3′            NM_003106.3           466
                 R: 5′-ATGTAGGTCTGCGAGCTGGT-3′                                   
  PPARγ          F: 5′-AAGACCACTCCCACTCCTTTG-3′           NM_005037.5           554
                 R: 5′-GTCAGCGGACTCTGGATTCA-3′                                   
  LPL            F: 5′-CTGAAGACACAGCTGAGGAC-3′            NM_000237.2           505
                 R: 5′-CTGAAGACACAGCTGAGGAC-3′                                   
  Osteocalcin    F: 5′-GTGCAGAGTCCAGCAAAGGT-3′            NM_199173.4           175
                 R: 5′-TCAGCCAACTCGTCACAGTC-3′                                   
  Collagen I      F: 5′-GTCGAGGGCCAAGACGAAG-3′             JQ236861.1           133
                 R: 5′-CAGATCACGTCATCGCACAA-3′                                   
  GAPDH          F: 5′-AAGTGGATATTGTTGCCATC-3′            NM_002046.4           454
                 R: 5′-ACTGTGGTCATGAGTCCTTC-3′                                   

Abbreviations: LPL, lipoprotein lipase; PPARγ, peroxisome proliferator-activated receptor gamma.
